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Summary
 Background: To determine the accuracy of several preoperative tests in predicting lymph node (LN) metastases 
and the feasibility of doing a routine lymphadenectomy in clinical stage-I endometrial cancer.
 Material/Methods: We reviewed 132 patients with clinical stage-I endometrial cancer. The preoperative tests used to 
predict LN metastases were serum CA-125 level, histologic type and grade, LN status assessed by 
pelvic magnetic resonance image (MRI) or computed tomography (CT), and depth of myometri-
al invasion assessed only by pelvic MRI. The cutoff value of the serum CA-125 level was determined 
using receiver operating characteristic curves. Multivariate logistic regression analyses were used 
to determine which tests are good predictors of LN metastases.
 Results: Of 132 patients, 13 (9.8%) had LN metastases. On univariate logistic regression analysis, a high 
CA-125 level and preoperative LN evaluation by pelvic MRI or CT were signifi cant predictors for 
LN metastases (OR=17.41, 95% CI: 4.36–69.56 and OR=14.30, 95% CI: 4.02–50.63, respectively). 
However, on multivariate logistic regression analysis adjusted for age and all preoperative tests, a 
high CA-125 level was the most signifi cant predictor (OR=13.73, 95% CI: 2.03–92.73). Among the 
97 patients with no signifi cant predictor of LN metastases, pelvic LN metastases were observed in 
3 patients (3.1%) and para-aortic LN metastases were observed in 1 patient (1.1%). Surgical com-
plications were mild (lymphocele, n=9; lymphedema, n=2; wound problem, n=2).
 Conclusions: Considering the importance of LN metastases as an indicator of prognosis, and the relatively low 
surgical risk of lymphadenectomy, clinicians should cautiously consider routine lymphadenecto-
my in patients with clinical stage-I endometrial cancer.
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Endometrial cancer is the most common gynecologic ma-
lignancy, with 41 200 new cases and 7350 deaths estimated 
in the United States in 2006 [1]. Because of Western infl u-
ences on South Korean lifestyles, the incidence of endome-
trial cancer in South Korea has increased. A lymph node 
(LN) metastasis is the most important prognostic factor in 
clinical early-stage endometrial cancer [2]. The incidence 
of pelvic LN metastases varies from 5% to 16% in clinical 
stage-I endometrial cancer. In women with clinical stage-I 
endometrial cancer, the 5-year disease-free survival rate for 
patients with LN metastases was 54% compared with 90% 
for patients without LN metastases [2–4].
In 1988, the International Federation of Gynecology and 
Obstetrics established the surgical staging system and in-
cluded retroperitoneal lymphadenectomy for managing 
endometrial cancer; however, it did not specify the type 
and extent of LN dissection. Since then, numerous stud-
ies have suggested the importance of pelvic and para-aor-
tic lymphadenectomy for defi ning the prognosis and pro-
viding important information about the need for adjuvant 
therapy [5]. However, doing a pelvic or para-aortic lymph-
adenectomy is controversial in clinical stage-I endometrial 
cancer. Some researchers consider complete evaluation of 
nodal status as mandatory [6,7]. Others have questioned 
the clinical utility of this procedure, especially for patients 
with a low risk of nodal involvement [8,9]. The known low-
risk factors for LN metastases include a superfi cial myome-
trial invasion (less than half), small tumor size (<2 cm), and 
a low tumor grade (grades 1 and 2) [10–12].
Identifying an accurate test to predict LN metastases in clin-
ical stage-I endometrial cancer could have clinical benefi ts. 
Surgical morbidity and time for lymphadenectomy could 
be decreased. Preoperatively predicting LN metastases can 
be done by examining the results of pelvic magnetic reso-
nance image (MRI) or computed tomography (CT) scan-
ning, or by determining the histologic type and grade of 
curettage or the preoperative serum CA-125 level [13,14]. 
We sought to determine the accurate predictor(s) of pelvic 
or para-aortic LN metastases among the above-mentioned 
preoperative tests and whether lymphadenectomy should 




The Seoul National University Hospital Tumor Registry 
was thoroughly reviewed to identify all of the patients with 
endometrial cancer who received surgical treatment from 
January 2000 to April 2006. Institutional review board ap-
proval was obtained in advance for this study. Within this 
hospital, 4 or 5 gynecologists are responsible for managing 
patients with gynecologic cancer. The type and extent of 
lymphadenectomy depends on the surgeon’s preference. 
One hundred thirty-two patients met the following inclu-
sion criteria: (1) clinical stage-I endometrial cancer, (2) pel-
vic surgery lymphadenectomy with or without para-aortic 
lymphadenectomy including hysterectomy, and (3) preop-
erative pelvic MRI or CT scanning done. The clinical ex-
tent of the tumor was evaluated in all patients and includ-
ed a chest radiograph. Serum CA-125 levels were measured 
preoperatively in all 132 patients except 7 (the medical re-
cords of these 7 were incomplete). The initial diagnosis of 
endometrial cancer was based on the results of endome-
trial biopsies obtained by hysteroscopy, curettage, or both. 
Preoperative curettage was done in all the patients except 
22; these 2 patients were operated on without curettage for 
suspected adenomyosis and leiomyoma. T. They were reop-
erated on after a diagnosis of endometrial cancer from the 
fi nal report had been made.
Preoperative tests used to predict LN metastases
We used histologic grade (grades 1 and 2 vs 3) and type 
(endometrioid type vs nonendometrioid type) of the pre-
operative curettage, serum CA-125 level, pelvic or para-aor-
tic LN status, and depth of myometrial invasion by pelvic 
imaging study as predictors of LN metastases. Because se-
rum CA-125 levels are affected by the estrogen status [15], 
132 patients were divided into 2 groups: those aged young-
er than 50 years and those aged 50 years and older. Cutoff 
levels of CA-125 were obtained using receiver operating 
characteristic (ROC) curves. The preoperative LN status 
was evaluated by pelvic MRI or CT scanning. The depth 
of preoperative myometrial invasion was evaluated by pel-
vic MRI only. All pelvic MRI examinations were done with 
a Magnetom 1.5 T scanner (Siemens, Erlangen, Germany) 
or a Signa 1.5 T scanner (General Electric Medical Systems, 
Milwaukee, WI, USA). All patients had spin-echo T1-weight-
ed images and T2-weighted fast-spin-echo images done. 
Gadolinium-enhanced T1-weighted fat saturation sequenc-
es were taken before and after intravenous injection of con-
trast media. A Somatom plus-4 scanner (Siemens Medical 
System, Erlangen, Germany) was used for CT scanning. 
Nonenhanced and contrast-enhanced scans were obtained 
in all patients. In all cases, scanning was initiated 60 seconds 
after an intravenous injection of 120 mL contrast material 
containing 300 mgI/mL (Ultravist 370, Schering, Berlin, 
Germany) at a rate of 3 mL/second. The scanning param-
eters included 7 mm/second table speed, 1:1 pitch, and 7 
to 8 mm thickness.
Surgical procedure
A median laparotomy was performed. After obtaining a 
peritoneal cytology specimen, all the intra-abdominal or-
gans and peritoneal surfaces were examined, and suspicious 
areas were biopsied. A total hysterectomy, bilateral salpin-
go-oophorectomy, and retroperitoneal lymphadenectomy 
were then done. Pelvic lymphadenectomy included mobiliz-
ing the external iliac artery and vein from the psoas muscle 
with en bloc removal of the lymphatic tissue overlying the 
external iliac vessels, the internal iliac artery, and the ob-
turator fossa above the obturator nerve. Para-aortic lymph-
adenectomy usually consists of removing the precaval and 
lower right and left aortic lymphatic tissue to the level of 
the inferior mesenteric artery.
Statistics
The t test was used to compare the mean values of age 
and parity between LN-positive and LN-negative groups. 
Univariate and multivariate logistic regression analyses were 
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used to discriminate the signifi cant risk factors for LN me-
tastases. The Kappa index and chi-square test (by linear as-
sociation) were used to analyze the association between 
variables. Statistical analyses were done with SPSS software 
(Statistical Product and Services Solutions, version 12.0, 
SPSS Inc, Chicago, IL, USA).
RESULTS
The mean age and parity of 132 patients were 53.8 years and 
2.1. There were 113 patients with stage-I (78%), 9 patients 
with stage-II (6.8%), 19 patients with stage-III (14.4%), and 
1 patient with stage-IV (0.8%) cancers. The endometrioid 
type was most common (n=126, 95.4%). We found papillary 
serous type in 3 patients (2.3%), clear cell type in 2 patients 
(1.5%), and poorly differentiated type in 1 patient (0.8%). 
Table 1 shows the postoperative characteristics of patients 
in the LN-negative and LN-positive groups.
Of 132 patients, 119 patients (90.2%) had no LN metastases 
and 13 patients (9.8%) had a LN metastasis. Among those 
13 patients, 5 patients (38.5%) had para-aortic LN metasta-
ses along with pelvic LN metastases. None of the patients had 
a para-aortic LN metastasis without a pelvic LN metastasis. A 
para-aortic lymphadenectomy was done in 19 (15.8%) of the 
119 patients with no LN metastases and in 7 (53.8%) of the 13 
patients with a LN metastasis. Two cutoff values for CA-125 lev-
els using ROC curves divided the patients into low- and high-
risk groups for pelvic LN metastases (20 U/mL for patients 
aged <50 years [AUC=0.734, sensitivity=0.667, specifi city=0.216] 
and 28 U/mL for patients aged ≥50 years [AUC=0.833, sensi-
tivity=0.800, specifi city=0.133]) (Figure 1).
The relations of the preoperative tests with LN metastases are 
shown in Table 2. Regarding age, no signifi cant difference 
was found for patients with LN metastases when compared 
with patients without LN metastases (P=0.095). On univari-
ate logistic regression analyses, a high CA-125 level and pre-
operative LN evaluation by pelvic MRI or CT were found to 
be signifi cant predictors for LN metastases, with OR=17.41 
(95% CI: 4.36–69.56) and OR=14.30 (95% CI: 4.02–50.63), 
respectively. On multivariate logistic regression analyses ad-
justed for age and all the preoperative tests, a high CA-125 
level was found to be the most signifi cant predictor of LN me-
tastases (OR=13.73, 95% CI: 2.03–92.73). There was a signif-
icant association between a high CA-125 level and preopera-
tive LN evaluation by pelvic MRI or CT (PP<0.001). A high 
preoperative CA-125 level was not associated with the depth 
of myometrial invasion (PP=0.315). Among the 97 patients 
with no signifi cant predictor of LN metastases, pelvic LN me-
tastases were observed in 3 patients (3.1%) and para-aortic 
LN metastases were observed in 1 patient (1.1%). Among 
the 13 patients with LN metastases, 3 patients (23.1%) had 
no signifi cant predictor for LN metastases.
Postoperative clinicopathologic characteristics according to 
LN metastases are shown in Table 3. The numbers of dis-
sected lymph nodes were not different between the groups. 
On multivariate logistic regression analyses, myometrial in-
vasion more than half was the only risk factor for LN metas-
tases (OR=5.38, 95% CI: 1.44–20.09).
A disagreement rate between preoperative grade and postop-
erative grade was 9.2% (kappa=0.455, P<0.001). A disagree-
ment rate between preoperative myometrial evaluation by 
pelvic MRI and postoperative myometrial invasion was 19.6% 
(kappa=0.663, P<0.001). The sensitivity, specifi city, and false-
positive and false-negative rates of the preoperative predic-
tors for LN metastases are summarized in Table 4.
DISCUSSION
The aim of this study was to determine the accuracy of sev-
eral preoperative tests that predict LN metastases and de-
termine the feasibility of doing routine lymphadenectomy 
in patients with clinical stage-I endometrial cancer. A high 
CA-125 level and preoperative LN evaluation by pelvic MRI 
or CT scanning were found to be signifi cant predictors of 
LN metastases. However, on multivariate logistic regression 
analyses adjusted for age and all the preoperative tests, a 
high CA-125 level was the most signifi cant predictor.
A previous study at our institution also showed that LN metas-
tases have the most signifi cant effect on elevating preoperative 
serum CA-125 levels (P=0.004) [16]. Higher CA-125 levels cor-
related with deep myometrial invasion (P=0.001). The cutoff 
value of preoperative serum CA-125 levels for LN metastases 
was 28.5 U/mL. Serum CA-125 levels are known to be affect-
ed by ovarian hormones and age. Therefore, we divided the 
patient population into 2 groups, by age, using 50 years as the 
dividing point. For preoperative serum CA-125 levels, the cut-
off values for LN metastases were 20 U/mL for patients aged 
<50 years and 28 U/mL for patients aged ≥50 years.
Todo and associates used cutoff values of preoperative se-






Patients  119  13
FIGO stage
 I  103 86.6%)
 II  9 7.6%)
 III  7 5.9%)  12 92.3%)
 IV  1 7.7%)
Postoperative grade
 1  74 62.2%)  3 23.1%)
 2  28 23.5%)  6 46.2%)
 3  15 12.6%)  4 30.8%)
Histologic type
 Endometrioid type  114 95.8%)  12 92.3%)
 Papillary serous type  2 1.7%)  1 7.7%)
 Clear cell type  2 1.7%)
 Poorly diff erentiated type  1 0.8%)
Table 1. Characteristics of 132 patients.
LN – lymph node.
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and 70U/mL for patients aged ≥50 years [13]. The differ-
ence between our study and the one by Todo and associates 
is the enrollment criteria. Because we included the only pa-
tients with clinical stage-I endometrial cancer, the propor-
tion of patients with advanced surgical stage (III or IV) in 
our study (15.2%) was lower than that of Todo and associates 
(26.6%). Therefore, the cutoff level of CA125 in our study is 
lower. Sood and associates also demonstrated that patients 
with positive pelvic or para-aortic LN metastases had signif-
icantly higher preoperative CA-125 levels [17]. In another 
study, preoperative serum CA-125 levels offered no informa-
tion with which to predict LN metastases in patients with en-
dometrial cancer [19]. In our study, although a cutoff value 
of a high CA-125 level was not useful in predicting the depth 
of myometrial invasion; higher CA-125 levels were correlat-
ed with deeper myometrial invasion (P<0.001).
MRI and CT scanning may be used to predict LN metasta-
ses. Nodal size is the current standard criteria for predict-
ing LN metastases on imaging study. Although a 1 cm di-
ameter is the preferred criterion, there is some variability 
with regard to size threshold [20,21]. However, it is not pos-
sible to differentiate metastatic nodes from hyperplastic 
nodes of a similar size. In 1993, Girardi and associates re-
ported that 37% of metastatic LNs were 2 mm or less in di-
ameter [22]. This explains the inaccuracy of MRI and CT 
scanning for predicting LN metastases. Sensitivities for LN 
metastases in gynecologic cancers range from 43% to 73% 
[23]. The sensitivity of MRI and CT for LN staging in our 
study was 61.5%.
The role of CT and MRI in evaluating LN status is contro-
versial [24]. On multivariate logistic regression analyses, 
preoperative pelvic MRI or CT was not found to be a sig-
nifi cant predictor of LN metastases. The chi-square test 
showed a signifi cant correlation between a high CA-125 
level and preoperative LN evaluation by pelvic MRI or CT 
(P<0.001), suggesting a confounding effect of preoperative 
LN evaluation by pelvic MRI or CT and a high CA-125 lev-
el. Consequently, we should realize that CT and MRI are 
only moderately sensitive for detecting LN metastases, and 
applying their results clinically is limited.
The junctional zone just beneath the endometrium on a 
T2-weighted image is an excellent indicator for determin-
ing myometrial invasion. In our study, preoperative evalua-
tion by pelvic MRI of the depth of myometrial invasion was 
not a signifi cant predictor for LN metastases. However, the 
depth of postoperative myometrial invasion was a signifi -
cant risk factor for LN metastases (P=0.008), suggesting that 
evaluating myometrial invasion by pelvic MRI is not an ac-
curate method for predicting LN metastases. A meta-anal-
ysis showed the sensitivity for deep myometrial invasion us-
ing contrast-enhanced imaging to be 78.6% to 100% with 
Preoperative test
LN metastasis
P OR (95% CI)* OR (95% CI)**
Negative (%) Positive (%)
Age, y (mean ±SD)  53.3±10.0  58.5±13.8 0.095
Parity (mean ±SD)  2.0±1.4  2.5±2.7  0.234
CA-125
 Low***  94 (83.9)  3 (23.1) 1.0 1.0
 High#  18 (16.1)  10 (76.9)  17.41 (4.36–69.56)  13.73 (2.03–92.73)
LN status by pelvic MRI or CT
 Negative  107 (89.9)  5 (38.5) 1.0 1.0
 Positive  12 (10.1)  8 (61.5)  14.30 (4.02–50.63)  3.68 (0.52–26.01)
MM invasion by pelvic MRI
 Less than half  74 (79.6)  5 (55.6) 1.0 1.0
 More than half  19 (20.4)  4 (44.4)  3.12 (0.76–12.74)  1.18 (0.17–8.2)
Histologic type
 Endometrioid  112 (95.7)  12 (92.3) 1.0 1.0
 Non-endometrioid##  5 (4.3)  1 (7.7)  1.87 (0.20–17.33)  0.87 (0.02–42.3)
Histologic grade
 1,2  91 (83.5)  10 (76.9) 1.0 1.0
 3  18 (16.5)  3 (23.1)  1.52 (0.38–6.06)  2.69 (0.24–29.9)
Table 2. Relationships between preoperative tests and postoperative LN metastasis.
LN – lymph node; MM – myometrium. * By univariate logistic regression analysis; ** By multivariate logistic regression analysis adjusted for age, 
CA-125, histologic grade and type, LN status by pelvic MRI or CT, MM invasion by pelvic MRI; *** Low: Level <20 (if age <50 yrs), level <28 (if age 
≥ 50yrs); # High: Level ≥20 (if age <50 yrs), level ≥28 (if age ≥5 0yrs). ## Non-endometrioid: Clear cell, serous papillary, poorly diff erentiated.
Clinical Research Med Sci Monit, 2008; 14(4): CR183-189
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a specifi city of 83.3% to 100% [25]. In our study,, the sensi-
tivity for deep myometrial invasion was 44.4% and the spec-
ifi city was 79.6%. Another study at our institution suggested 
that polypoid tumor and junctional zone isointense to myo-
metrium are factors associated with false-negative results of 
myometrial invasion on pelvic MRI [26].
Characteristics
LN metastasis
OR (95% CI)* OR (95% CI)**
Negative (%) Positive (%)
Patients  119 (90.2)  13 (9.8)
Number of dissected LNs (mean ±SD) 24.6±12.0 29.5±8.4  1.04 (0.99–1.09)  1.01 (0.96–1.08)
Histology 119 13  0.91 (0.07–12.32)  0.95 (0.07–12.80)
Endometrioid  114 (95.1)  12 (92.3)
Non-endometrioid***  5 (4.9)  1 (7.7)
Grade 117 13  1.56 (0.33–7.26)  1.40 (0.28–7.10)
1,2  102 (87.2)  9 (69.2)
3  15 (12.8)  4 (30.8)
MM involvement 119 13  5.82 (1.62–20.87)  5.38 (1.44–20.09)
Less than half  96 (80.7)  5 (38.5)
More than half  23 (19.3)  8 (61.5)
Table 3. Postoperative clinicopathologic characteristics and LN metastasis.
LN – lymph node; LNs – lymph nodes; MM, myometrium; * By univariate logistic regression analysis; ** By multivariate logistic regression analysis 
adjusted for number of dissected LNs, histology, grade, MM involvement; *** Non-endometrioid: Clear cell, serous papillary, poorly diff erentiated.
Predictor No. Sensitivity Specifi city False positive rate False negative rate
High CA-125 level* 125 76.9% 83.9% 64.3% 3.1%
LN status by pelvic MRI or CT 132 61.5% 90.0% 60.0% 4.4%
Histologic grade 3 122 23.1% 83.5% 85.7% 9.9%
MM invasion by pelvic MRI** 102 44.4% 79.6% 82.6% 6.3%
Histologic type*** 130 7.7% 95.7% 83.3% 9.7%
Table 4. Sensitivity, specifi city, and false positive/negative rate of preoperative predicors for LN metastasis.
LN – lymph node; No – the number of patients; MM – myometrium; * High: Level ≥20 (if age <50 yrs), level ≥28 (if age ≥50 yrs); ** MM invasion 
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Histologic grade is strongly correlated with LN metasta-
ses in endometrial cancer. However, this result is based on 
the histologic grade assigned at fi nal pathology [27]. Most 
studies report an upgrade of the grade of preoperative cu-
rettage in at least 20% of cases [28]. In our study, we found 
that 26.3% of the patients that were classifi ed as high risk 
(grade 3) after evaluation of the hysterectomy specimen 
previously had been classifi ed as low risk (grade 1 and 2). 
Furthermore, attempts to improve these results by examin-
ing frozen sections during the operation also were unsuc-
cessful; the specifi city was 98% and the accuracy was 87%, 
but the sensitivity was as low as 40% [29]. Serous, poorly 
differentiated, and clear cell adenocarcinomas of the endo-
metrium have been shown to be associated with poor sur-
vival [30]. Although our study shows poor predictability of 
LN metastases by histologic type, this result may be associ-
ated with the small number of cases (n=6).
Although a high CA-125 level was the most signifi cant pre-
dictor of LN metastases, the sensitivity (76.9%) was relative-
ly low to predict LN metastases and the false-negative rate 
was 3.1%. Developing new tests is necessary to predict ac-
curate LN evaluation.
The additional surgical morbidity and time for pelvic lymph-
adenectomy are minimal [3]. In our study, surgical compli-
cations were mild (lymphocele [n=9], lymphedema [n=2], 
and wound problems [n=2, umbilical hernia and wound de-
hiscence]). Approximately 10% to 20% of endometrial can-
cer patients have severe medical conditions that preclude 
surgery [31]; these patients tend to be morbidly obese [32]. 
The body mass index cutoff for assessing obesity for the 
Asians, such as the Koreans, is lower than that in Western 
populations (25.0 kg/m2 vs 30.0 kg/m2, respectively) [33]. 
The prevalence of Korean women with body mass indexes 
>30.0 kg/m2 is 0.7% [34], compared with 31% of women in 
the United States. In fact, few patients in this study were in-
operable because of severe obesity. Inoperability because of 
obesity is rare in Korean women with endometrial cancer.
CONCLUSIONS
Because of its low sensitivity to preoperative tests, the clini-
cal signifi cance of LN metastases, the discrepancy between 
clinical and surgical staging, and the low surgical morbidity 
from lymphadenectomy, clinicians should cautiously consid-
er routine lymphadenectomy in patients with clinical stage-
I endometrial cancer.
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